Monoclonal Antibodies (mAbs) Market with End User Segments and Top Companies Offering during 2018 – 2026 | Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Merck & Co. Inc., Eli Lily & Co., AstraZeneca, Amgen Inc., Abbott Laboratories and Thermo Fisher Sc

According to a new study published by Polaris Market Research the Monoclonal Antibodies (mAbs) Market is anticipated to reach over USD 148.9 billion by 2026.

Monoclonal Antibodies (mAbs) Market is mainly driven by an active pipeline, wherein many monoclonal antibodies are at the different stages of drug development. In addition, increased in research and development, favourable government policies and rising prevalence of cancer and other chronic diseases supplement the market growth. The other factors that augment that market growth include the increasing the demand for personalized medicine and rising awareness among medical professional and patients about the latest medical therapies. Moreover, emerging targets such as central nervous system disorders, price correction and new delivery strategies for monoclonal antibodies provide opportunities for market growth in the near future.

Request for Sample Copy of this research report @
http://bit.ly/2R8QSrL

In 2017, by indication, the cancer segment dominated the market in terms of revenue, wherein fully-human monoclonal antibodies held a major share of the market. In terms of geography, North America accounted for the majority share in the Monoclonal Antibodies (mAbs) Market.

There has been an increase in the research and development activities in the field of Monoclonal Antibodies (mAbs) Market. Several biomedical and technological advances in genetic engineering and next generation genome sequencing have fuelled the growth of the monoclonal antibody market. Also, multiple new targets have been identified during preclinical research, which has led to the development and production of newer monoclonal antibodies by using various cytotechnological methodologies. In addition to this, favorable government initiatives to enable cost-effective production of monoclonal antibodies would give impetus to the monoclonal antibodies market growth. Also, pre-defined guidelines by regulatory bodies would ensure the safe, effective and high-quality manufacturing of monoclonal antibodies Recently, the European Commission approved the first biosimilar mAb Celltrion’s Truxima (biosimilar rituximab), thereby boding well for its potential approval in the U.S.

Following are the Top Key Players in Monoclonal Antibodies (mAbs) Market: -

Pfizer, Inc.
GlaxoSmithKline PLC
Novartis AG
Merck & Co. Inc.
Eli Lily & Co.
AstraZeneca
Amgen, Inc.
Abbott Laboratories
Thermo Fisher Scientific Inc.
Bistro-Myers Squibb. Mylan N.V.
Daiichi Sankyo Company Ltd.
Bayer AG
Hoffmann-La Roche Ltd.
Novo Nordisk A/S.

Enquire Before Buying this research report @
http://bit.ly/2RbdNmu

Personalized medicine is being redefined by monoclonal antibodies that are the cutting-edge form of immunotherapy. The surge in the demand for personalized medicine plays a crucial role in boosting the monoclonal antibodies market by giving an impetus to the development of personalized drug targets as every patient responds differently to different treatment regimens. Moreover, other factors such as specificity, homogeneity and relatively fewer adverse events that entail usage of personalized medicine contribute to significant Monoclonal Antibodies (mAbs) Market growth.

The widespread and rapidly increasing prevalence of cancer and other chronic diseases have resulted in the soaring demand of biological medicines, thereby augmenting the growth of monoclonal antibodies. Furthermore, several other monoclonal antibodies used in treatment of deadly infections such as HIV/AIDS, Ebola and Zika viral disease are in various phases of clinical trials. Also, high spending power of patients in developed countries, increasing disposable incomes in developing countries and better healthcare facilities further facilitate market growth. Going forward, increasing awareness about the latest medical therapies among medical professional and patients, and increasing utilization of monoclonal antibodies in treatment regimens is anticipated to propel the Monoclonal Antibodies (mAbs) Market growth.

Based on indication, Monoclonal Antibodies (mAbs) Market is segmented in to cancer, inflammation, cardiovascular diseases, transplant rejection, respiratory and infectious diseases. The cancer segment is expected to lead the market during the forecast period owing to rapidly expanding patient pool, awareness about monoclonal antibodies among physicians and patients, improving medical facilities, high spending power in developed countries and increasing disposable incomes in developing countries.

TOC of Monoclonal Antibodies (mAbs) Market:

Chapter 1. Overview and Scope

Chapter 2. Market Summary

Chapter 3. Monoclonal Antibodies (mAbs) Market Size and Forecast

Chapter 4. Dynamics and Segmentation

Chapter 5. Detailed Insight on Key Company

Chapter 6. Research Methodology and Reference

Chapter 7. Competitive Landscape

TOC Continued…...!!!

About Us:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.

Contact Us:
Mr. Neel
Corporate Sales, USA
Polaris Market Research and Consulting
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com

This release was published on openPR.